atezolizumab plus carboplatin plus paclitaxel (n=338) vs. nab-paclitaxel (n=340)
randomized controlled trial
atezolizumab plus carboplatine plus paclitaxel (ACP)
Atezolizumab was administered at 1200 mg intravenously and paclitaxel at 200 mg/m2 IV (175 mg/m2 for Asian race/ethnicity; day 1)
carboplatine plus nabpaclitaxel (CnP)
carboplatin at an area under the concentration-time curve of 6 mg/mL/min IV (day 1), nab-paclitaxel at 100 or 200 mg/m2 IV (days 1, 8, and 15)
Crossover to atezolizumab was not allowed
squamous - mNSCLC - L1 - all population
Patients known to have EGFR mutations or ALK fusion oncogene were eligible
open label
317 study sites across 26 countries
P3/ two sided and two interim analysis. Alpha split between coprimary endpoint (ACnP) and hierarchy with OS/PFS (ACP)
Adding atezolizumab to platinum-based chemotherapy significantly improved PFS in patients with first-line squamous NSCLC; OS was similar between the arms.No efficay results for this arm because of hierarchy